# NFlection Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nflection-therapeutics

- Industry: Biotechnology
- Headquarters: Wayne, US
- Website: www.nflectionrx.com
- Total disclosed funding: $20M
- Latest round: Series A (Jun 9, 2020)
- Investors on record: 2

## About

NFlection Therapeutics is a biopharmaceutical company focused on developing targeted topical therapies for rare disorders linked to RAS pathway activation, offering innovative solutions for dermatological conditions.NFlection Therapeutics, Inc. specializes in the development of novel therapies aimed at addressing rare dermatological disorders. Founded in 2014 in Wayne, US, the company has raised a total of USD 20.00 mn in funding through a SERIES A round co-led by F-Prime Capital and VenBio Partners in June 2020. The company was established by Scott Plotkin and currently operates under the leadership of CEO Christopher Powala and William Hodder.NFlection Therapeutics specializes in the discovery and development of targeted topical therapies aimed at addressing rare disorders associated with the aberrant activation of the RAS pathway. The company's core product offerings include first-in-class MEK inhibitors, which are being developed for the treatment of conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevi sebacei. These novel therapies aim to provide patients with effective, localized treatment options that minimize systemic exposure while targeting the underlying molecular causes of their conditions. NFlection's therapies primarily serve patients in North America and certain European markets, focusing on dermatological disorders that currently have limited treatment options.NFlection Therapeutics generates revenue through strategic partnerships and collaborations that facilitate the development and commercialization of its proprietary therapies. The company engages in transactions with healthcare providers and institutions, operating under a direct-to-consumer model for its flagship products once they are approved for market release. While specific pricing structures for their products are not disclosed, the company implements a pricing strategy reflective of the specialty pharmaceutical market, focusing on reimbursement from healthcare systems and insurance providers. By aligning its product offerings with the needs of a targeted patient population and leveraging partnerships, NFlection aims to establish a sustainable revenue stream as it advances its product candidates through clinical development.NFlection Therapeutics plans to leverage recent funding from its SERIES A round to support the advancement of its product candidates through clinical development. The company aims to introduce new products targeting rare dermatological conditions in the coming years, expanding its market presence in North America and select European markets. By strategically utilizing the USD 20.00 mn raised, NFlection is positioned to enhance its research capabilities and expedite the clinical trials necessary for bringing its therapies to market.

## Funding rounds

- Series A, Jun 9, 2020, $20M — F-Prime Capital, VenBio

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A